Champions Oncology
CSBR
30 hedge funds and large institutions have $50.4M invested in Champions Oncology in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 2 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.08% less ownership
Funds ownership: 45.91% → 45.82% (-0.08%)
3% less capital invested
Capital invested by funds: $51.7M → $50.4M (-$1.38M)
3% less funds holding
Funds holding: 31 → 30 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$129K |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$69.4K |
| 3 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
+$22.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$22K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$167K |
| 2 |
OMC
Overbrook Management Corp
New York
|
-$141K |
| 3 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$57.7K |
| 4 |
MTWM
Masso Torrence Wealth Management
Marlton,
New Jersey
|
-$8K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$7.33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $55K | -$5.84K | -728 | -10% |
|
|
27
UBS Group
Zurich,
Switzerland
| $24K | +$22K | +2,742 | +979% |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
MTWM
29
Masso Torrence Wealth Management
Marlton,
New Jersey
| – | -$8K | -1,000 | Closed |
|
30
Bank of America
Charlotte,
North Carolina
| – | -$1K | -147 | Closed |
|
31
Wells Fargo
San Francisco,
California
| – | +$8 | +1 | +3% |
|
CSBR Hedge Fund Activity: Q1 2022 in Review
30 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q1 2022, worth a combined $50.4M — down 2.7% from $51.7M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CSBR and 1 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 8 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $129K. The largest seller was Renaissance Technologies, cutting an estimated $167K.
- 30 institutional investors held Champions Oncology (CSBR) as of Q1 2022, down from 31 in Q4 2021.
- Funds reported $50.4M of Champions Oncology stock for Q1 2022, down 2.7% quarter-over-quarter.
- 1 fund opened new Champions Oncology positions in Q1 2022 and 2 closed out, a net change of -1 holder.
- The largest Champions Oncology buyer in Q1 2022 was Citadel Advisors, an estimated $129K added.
- The largest Champions Oncology seller in Q1 2022 was Renaissance Technologies, an estimated $167K sold.
Based on aggregated 13F filings for Q1 2022.